ConductScience.org, home

Paper42434847

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Montesinos P and 23 others. Future Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Papers, record 42434847. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42434847

Download JSON
Disease
acute myeloid leukemia587 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
PubMed
Journal
Future Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-27
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Montesinos PPau
2Altman JKJessica K
3Bullinger LLars
4Cheong JWJune-Won
5Fathi ATAmir T
6Levis MJMark J
7Luger SSelina
8Miyamoto TToshihiro
9Oliva ENEsther Natalie
10Perl AEAlexander E
11Récher CChristian
12Veiga RRRebeca Rodriquez
13Wang JJianxiang
14Zeidan AMAmer M
15Liu LLi
16Duong YYvonne
17Rohrbach JECJaime E Connolly
18Inghirami GGiorgio
19Alexis KKarenza
20Gosberg AAndreas

Source PubMed

See all 24 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
fms-Like Tyrosine Kinase 3Major topic
Leukemia, Myeloid, AcuteMajor topic
Phenylurea CompoundsMajor topic
BenzothiazolesMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Double-Blind Method
Adult
Female
Male
Treatment Outcome
Middle Aged
Aged
Young Adult

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022https://conductscience.org/library/papers/35797463PubMed
28182945Expression of the FLT3 gene in human leukemia-lymphoma cell lines.Leukemia1994https://conductscience.org/library/papers/8182945PubMed
337116523
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet2023https://conductscience.org/library/papers/37116523PubMed
418309032An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.Blood2008https://conductscience.org/library/papers/18309032PubMed
514673054
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
J Clin Oncol2003https://conductscience.org/library/papers/14673054PubMed
641949390Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.Blood Adv2026https://conductscience.org/library/papers/41949390PubMed
726376137Acute Myeloid Leukemia.N Engl J Med2015https://conductscience.org/library/papers/26376137PubMed
839392050In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Mol Med Rep2024https://conductscience.org/library/papers/39392050PubMed
929257272High expression of FLT3 is a risk factor in leukemia.Mol Med Rep2018https://conductscience.org/library/papers/29257272PubMed
1030651634Targeting FLT3 mutations in AML: review of current knowledge and evidence.Leukemia2019https://conductscience.org/library/papers/30651634PubMed
1131821677FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.Cancer Sci2020https://conductscience.org/library/papers/31821677PubMed
1227367478'Acute myeloid leukemia: a comprehensive review and 2016 update'.Blood Cancer J2016https://conductscience.org/library/papers/27367478PubMed
1333603142Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.Leukemia2021https://conductscience.org/library/papers/33603142PubMed
1440008144Bone marrow immune cells and drug resistance in acute myeloid leukemia.Exp Biol Med (Maywood)2025https://conductscience.org/library/papers/40008144PubMed
158637232Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.Leukemia1996https://conductscience.org/library/papers/8637232PubMed
1612200684Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.Leukemia2002https://conductscience.org/library/papers/12200684PubMed
1732215183Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.Oncotarget2020https://conductscience.org/library/papers/32215183PubMed
189737679Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.Leukemia1998https://conductscience.org/library/papers/9737679PubMed
1924002496Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.J Clin Oncol2013https://conductscience.org/library/papers/24002496PubMed
2033425766FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies.Front Oncol2020https://conductscience.org/library/papers/33425766PubMed

See all 33 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
QUIZARTINIBCHEMBL576982Derived from the trial1https://conductscience.org/library/drugs/CHEMBL576982

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42434847

GET https://conductscience.org/api/papers/v1/42434847/authors?page=2